Business Development

Leader’s in Alzheimer’s disease research, TauRx has a strong and defensible intellectual property position. Over the past 23 years of research in the tau pathology of Alzheimer’s disease, Professor Wischik’s team has generated a multi-layered portfolio of patents and patent applications which TauRx believes will permit a strong defensive intellectual property position. This consists of over 678 granted patents in 25 patent families, with a further 145 patents pending. The core patents provide cover through 2032.

Having pioneered a new pathway towards effective treatment and prevention of Alzheimer’s, the company’s success to date is also due to collaborations with organisations that span a variety of fields. Achieving the company’s long term vision and commercial goals will require further alliances and TauRx is pleased to consider new partnerships with pharmaceutical companies active in the field of neurodegeneration.

Should your company match the business development interests of TauRx as outlined above, please contact us